As Clover strives to deliver next-generation solutions for patients all around the world, the company’s in-house commercial manufacturing capabilities allow the company to increase the speed and efficiency of large scale biologics production, and ensure these drugs get into the hands of patients who need them as quickly as possible, while still maintaining the quality standards and GMP systems.
Especially during the COVID-19 pandemic, the speed of developing and supplying large quantities of safe and effective vaccines to the world population is extremely critical. At Clover, we have in-house manufacturing capacity to produce more than one billion doses of the COVID-19 vaccine antigen annually.
With the continuous and rapid growth at Clover, we are constantly innovating and upgrading our manufacturing capabilities to ensure the global population’s demand for safe, efficacious and high-quality vaccines are met.
Our cGMP manufacturing facility located in Changxing, Zhejiang, China is equipped with state-of-the-art 4 x 2,000L single-use bioreactor (SUB) capacity and utilizing Cytiva’s Flexfactory© biomanufacturing platform for upstream and purification process of drug substance manufacturing. We also have multiple commercial-scale drug product (DP) fill-finish lines onsite including prefilled syringe, glass vials and lyophilization. The manufacturing facility enables production for our late-stage clinical programs and large-scale commercial production.
No.168, Chengwanng Road
Changxing, Huzhou, Zhejiang, China
The pilot facility is located in Chengdu, Sichuan, China. This site has 200L single-use and 150L stainless steel bioreactor capacity as well as multiple pilot-scale drug product (DP) filling lines. The pilot facility supplies material for pre-clinical, IND and early-stage clinical trials.
Block B, Building 1
Chengdu Hi-Tech Incubation Park
Tianfu Avenue,
Chengdu, Sichuan, China
